Regulation by chronic treatment with cabergoline of dopamine D1 and D2 receptor levels and their expression in the striatum of Parkinsonian-Monkeys
Identifieur interne : 003562 ( Main/Exploration ); précédent : 003561; suivant : 003563Regulation by chronic treatment with cabergoline of dopamine D1 and D2 receptor levels and their expression in the striatum of Parkinsonian-Monkeys
Auteurs : M. Goulet [Canada] ; R. Grondin [Canada] ; M. Morissette [Canada] ; S. Maltais [Canada] ; P. Falardeau [Canada] ; P. J. Bedard [Canada] ; T. Di Paolo [Canada]Source :
- Progress in neuro-psychopharmacology & biological psychiatry [ 0278-5846 ] ; 2000.
Descripteurs français
- Pascal (Inist)
- Parkinson maladie, Cabergoline, Antiparkinsonien, Agoniste, Stimulant dopaminergique, Récepteur dopaminergique D1, Récepteur dopaminergique D2, Expression génique, Voie souscutanée, Long terme, Animal, Singe, Traitement, Chimiothérapie, Encéphale, Système nerveux central, Corps strié, Mécanisme action, Activité biologique, Ergot dérivé, Interaction moléculaire, Tolérance.
- Wicri :
- topic : Singe.
English descriptors
- KwdEn :
- Agonist, Animal, Animals, Antiparkinson Agents (administration & dosage), Antiparkinson Agents (pharmacology), Antiparkinson agent, Binding Sites, Biological activity, Brain (vertebrata), Cabergoline, Central nervous system, Chemotherapy, Corpus striatum, D1 Dopamine receptor, D2 Dopamine receptor, Disease Models, Animal, Dopamine agonist, Ergolines (administration & dosage), Ergolines (pharmacology), Ergot derivatives, Female, Gene expression, In Situ Hybridization, Long term, Macaca fascicularis, Mechanism of action, Molecular interaction, Monkey, Parkinson Disease (drug therapy), Parkinson Disease (physiopathology), Parkinson disease, Receptors, Dopamine D1 (drug effects), Receptors, Dopamine D1 (physiology), Receptors, Dopamine D2 (drug effects), Receptors, Dopamine D2 (physiology), Subcutaneous administration, Tolerance, Treatment.
- MESH :
- chemical , administration & dosage : Antiparkinson Agents, Ergolines.
- chemical , drug effects : Receptors, Dopamine D1, Receptors, Dopamine D2.
- chemical , pharmacology : Antiparkinson Agents, Ergolines.
- drug therapy : Parkinson Disease.
- chemical , physiology : Receptors, Dopamine D1, Receptors, Dopamine D2.
- physiopathology : Parkinson Disease.
- Animals, Binding Sites, Disease Models, Animal, Female, In Situ Hybridization, Macaca fascicularis.
Abstract
1. Chronic treatment for one month with the long-acting dopamine D2-like agonist cabergoline (0.25 mg/kg s.c. every 48 hours), had despite partial tolerance, sustained antiparkinsonian activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) Parkinsonian monkeys (Macaca fascicularis). 2. Cabergoline treatment decreased by half striatal D2 receptor binding density measured by [3H]spiperone autoradiography versus untreated MPTP monkeys. No change in D2 mRNA measured by in situ hybridization and D2 receptor immunostaining was observed. 3. No change in either D1 receptor binding density or Dl receptor mRNA levels was observed in cabergoline-treated MPTP-monkeys compared to untreated MPTP-monkeys, suggesting receptor subfamily specificity of cabergoline. 4. The present results suggest that the cabergoline-induced behavioral partial tolerance is accompanied by a decrease in D2 receptor binding but not due to alterations in the steady state of D2 mRNA levels.
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000C89
- to stream PascalFrancis, to step Curation: 000035
- to stream PascalFrancis, to step Checkpoint: 000B60
- to stream Main, to step Merge: 003A94
- to stream PubMed, to step Corpus: 001644
- to stream PubMed, to step Curation: 001644
- to stream PubMed, to step Checkpoint: 001644
- to stream Ncbi, to step Merge: 000117
- to stream Ncbi, to step Curation: 000117
- to stream Ncbi, to step Checkpoint: 000117
- to stream Main, to step Merge: 003860
- to stream Main, to step Curation: 003562
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Regulation by chronic treatment with cabergoline of dopamine D1 and D2 receptor levels and their expression in the striatum of Parkinsonian-Monkeys</title><author><name sortKey="Goulet, M" sort="Goulet, M" uniqKey="Goulet M" first="M." last="Goulet">M. Goulet</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Faculty of Pharmacy, Laval University and Department of Molecular Endocrinology, Laval University Medical Centre</s1><s2>Ste-Foy, Québec</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Ste-Foy, Québec</wicri:noRegion></affiliation></author><author><name sortKey="Grondin, R" sort="Grondin, R" uniqKey="Grondin R" first="R." last="Grondin">R. Grondin</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Medicine, Faculty of Medicine, Laval University and Neuroscience Unit, Laval University Medical Centre</s1><s2>Ste-Foy, Québec</s2><s3>CAN</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Ste-Foy, Québec</wicri:noRegion></affiliation></author><author><name sortKey="Morissette, M" sort="Morissette, M" uniqKey="Morissette M" first="M." last="Morissette">M. Morissette</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Medicine, Faculty of Medicine, Laval University and Neuroscience Unit, Laval University Medical Centre</s1><s2>Ste-Foy, Québec</s2><s3>CAN</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Ste-Foy, Québec</wicri:noRegion></affiliation></author><author><name sortKey="Maltais, S" sort="Maltais, S" uniqKey="Maltais S" first="S." last="Maltais">S. Maltais</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Faculty of Pharmacy, Laval University and Neuroscience Unit, Laval University Medical Centre</s1><s2>Ste-Foy, Quebec</s2><s3>CAN</s3><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Ste-Foy, Quebec</wicri:noRegion></affiliation></author><author><name sortKey="Falardeau, P" sort="Falardeau, P" uniqKey="Falardeau P" first="P." last="Falardeau">P. Falardeau</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Faculty of Pharmacy, Laval University and Neuroscience Unit, Laval University Medical Centre</s1><s2>Ste-Foy, Quebec</s2><s3>CAN</s3><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Ste-Foy, Quebec</wicri:noRegion></affiliation></author><author><name sortKey="Bedard, P J" sort="Bedard, P J" uniqKey="Bedard P" first="P. J." last="Bedard">P. J. Bedard</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Medicine, Faculty of Medicine, Laval University and Neuroscience Unit, Laval University Medical Centre</s1><s2>Ste-Foy, Québec</s2><s3>CAN</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Ste-Foy, Québec</wicri:noRegion></affiliation></author><author><name sortKey="Di Paolo, T" sort="Di Paolo, T" uniqKey="Di Paolo T" first="T." last="Di Paolo">T. Di Paolo</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Faculty of Pharmacy, Laval University and Department of Molecular Endocrinology, Laval University Medical Centre</s1><s2>Ste-Foy, Québec</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Ste-Foy, Québec</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">00-0338490</idno><date when="2000">2000</date><idno type="stanalyst">PASCAL 00-0338490 INIST</idno><idno type="RBID">Pascal:00-0338490</idno><idno type="wicri:Area/PascalFrancis/Corpus">000C89</idno><idno type="wicri:Area/PascalFrancis/Curation">000035</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000B60</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000B60</idno><idno type="wicri:doubleKey">0278-5846:2000:Goulet M:regulation:by:chronic</idno><idno type="wicri:Area/Main/Merge">003A94</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:10958154</idno><idno type="wicri:Area/PubMed/Corpus">001644</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001644</idno><idno type="wicri:Area/PubMed/Curation">001644</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001644</idno><idno type="wicri:Area/PubMed/Checkpoint">001644</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001644</idno><idno type="wicri:Area/Ncbi/Merge">000117</idno><idno type="wicri:Area/Ncbi/Curation">000117</idno><idno type="wicri:Area/Ncbi/Checkpoint">000117</idno><idno type="wicri:doubleKey">0278-5846:2000:Goulet M:regulation:by:chronic</idno><idno type="wicri:Area/Main/Merge">003860</idno><idno type="wicri:Area/Main/Curation">003562</idno><idno type="wicri:Area/Main/Exploration">003562</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Regulation by chronic treatment with cabergoline of dopamine D1 and D2 receptor levels and their expression in the striatum of Parkinsonian-Monkeys</title><author><name sortKey="Goulet, M" sort="Goulet, M" uniqKey="Goulet M" first="M." last="Goulet">M. Goulet</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Faculty of Pharmacy, Laval University and Department of Molecular Endocrinology, Laval University Medical Centre</s1><s2>Ste-Foy, Québec</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Ste-Foy, Québec</wicri:noRegion></affiliation></author><author><name sortKey="Grondin, R" sort="Grondin, R" uniqKey="Grondin R" first="R." last="Grondin">R. Grondin</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Medicine, Faculty of Medicine, Laval University and Neuroscience Unit, Laval University Medical Centre</s1><s2>Ste-Foy, Québec</s2><s3>CAN</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Ste-Foy, Québec</wicri:noRegion></affiliation></author><author><name sortKey="Morissette, M" sort="Morissette, M" uniqKey="Morissette M" first="M." last="Morissette">M. Morissette</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Medicine, Faculty of Medicine, Laval University and Neuroscience Unit, Laval University Medical Centre</s1><s2>Ste-Foy, Québec</s2><s3>CAN</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Ste-Foy, Québec</wicri:noRegion></affiliation></author><author><name sortKey="Maltais, S" sort="Maltais, S" uniqKey="Maltais S" first="S." last="Maltais">S. Maltais</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Faculty of Pharmacy, Laval University and Neuroscience Unit, Laval University Medical Centre</s1><s2>Ste-Foy, Quebec</s2><s3>CAN</s3><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Ste-Foy, Quebec</wicri:noRegion></affiliation></author><author><name sortKey="Falardeau, P" sort="Falardeau, P" uniqKey="Falardeau P" first="P." last="Falardeau">P. Falardeau</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Faculty of Pharmacy, Laval University and Neuroscience Unit, Laval University Medical Centre</s1><s2>Ste-Foy, Quebec</s2><s3>CAN</s3><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Ste-Foy, Quebec</wicri:noRegion></affiliation></author><author><name sortKey="Bedard, P J" sort="Bedard, P J" uniqKey="Bedard P" first="P. J." last="Bedard">P. J. Bedard</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Medicine, Faculty of Medicine, Laval University and Neuroscience Unit, Laval University Medical Centre</s1><s2>Ste-Foy, Québec</s2><s3>CAN</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Ste-Foy, Québec</wicri:noRegion></affiliation></author><author><name sortKey="Di Paolo, T" sort="Di Paolo, T" uniqKey="Di Paolo T" first="T." last="Di Paolo">T. Di Paolo</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Faculty of Pharmacy, Laval University and Department of Molecular Endocrinology, Laval University Medical Centre</s1><s2>Ste-Foy, Québec</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Ste-Foy, Québec</wicri:noRegion></affiliation></author></analytic><series><title level="j" type="main">Progress in neuro-psychopharmacology & biological psychiatry</title><title level="j" type="abbreviated">Prog. neuro-psychopharmacol. biol. psychiatr.</title><idno type="ISSN">0278-5846</idno><imprint><date when="2000">2000</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Progress in neuro-psychopharmacology & biological psychiatry</title><title level="j" type="abbreviated">Prog. neuro-psychopharmacol. biol. psychiatr.</title><idno type="ISSN">0278-5846</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Agonist</term><term>Animal</term><term>Animals</term><term>Antiparkinson Agents (administration & dosage)</term><term>Antiparkinson Agents (pharmacology)</term><term>Antiparkinson agent</term><term>Binding Sites</term><term>Biological activity</term><term>Brain (vertebrata)</term><term>Cabergoline</term><term>Central nervous system</term><term>Chemotherapy</term><term>Corpus striatum</term><term>D1 Dopamine receptor</term><term>D2 Dopamine receptor</term><term>Disease Models, Animal</term><term>Dopamine agonist</term><term>Ergolines (administration & dosage)</term><term>Ergolines (pharmacology)</term><term>Ergot derivatives</term><term>Female</term><term>Gene expression</term><term>In Situ Hybridization</term><term>Long term</term><term>Macaca fascicularis</term><term>Mechanism of action</term><term>Molecular interaction</term><term>Monkey</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (physiopathology)</term><term>Parkinson disease</term><term>Receptors, Dopamine D1 (drug effects)</term><term>Receptors, Dopamine D1 (physiology)</term><term>Receptors, Dopamine D2 (drug effects)</term><term>Receptors, Dopamine D2 (physiology)</term><term>Subcutaneous administration</term><term>Tolerance</term><term>Treatment</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparkinson Agents</term><term>Ergolines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>Receptors, Dopamine D1</term><term>Receptors, Dopamine D2</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiparkinson Agents</term><term>Ergolines</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" type="chemical" qualifier="physiology" xml:lang="en"><term>Receptors, Dopamine D1</term><term>Receptors, Dopamine D2</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Binding Sites</term><term>Disease Models, Animal</term><term>Female</term><term>In Situ Hybridization</term><term>Macaca fascicularis</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term><term>Cabergoline</term><term>Antiparkinsonien</term><term>Agoniste</term><term>Stimulant dopaminergique</term><term>Récepteur dopaminergique D1</term><term>Récepteur dopaminergique D2</term><term>Expression génique</term><term>Voie souscutanée</term><term>Long terme</term><term>Animal</term><term>Singe</term><term>Traitement</term><term>Chimiothérapie</term><term>Encéphale</term><term>Système nerveux central</term><term>Corps strié</term><term>Mécanisme action</term><term>Activité biologique</term><term>Ergot dérivé</term><term>Interaction moléculaire</term><term>Tolérance</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Singe</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">1. Chronic treatment for one month with the long-acting dopamine D2-like agonist cabergoline (0.25 mg/kg s.c. every 48 hours), had despite partial tolerance, sustained antiparkinsonian activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) Parkinsonian monkeys (Macaca fascicularis). 2. Cabergoline treatment decreased by half striatal D2 receptor binding density measured by [<sup>3</sup>H]spiperone autoradiography versus untreated MPTP monkeys. No change in D2 mRNA measured by in situ hybridization and D2 receptor immunostaining was observed. 3. No change in either D1 receptor binding density or Dl receptor mRNA levels was observed in cabergoline-treated MPTP-monkeys compared to untreated MPTP-monkeys, suggesting receptor subfamily specificity of cabergoline. 4. The present results suggest that the cabergoline-induced behavioral partial tolerance is accompanied by a decrease in D2 receptor binding but not due to alterations in the steady state of D2 mRNA levels.</div></front></TEI><affiliations><list><country><li>Canada</li></country></list><tree><country name="Canada"><noRegion><name sortKey="Goulet, M" sort="Goulet, M" uniqKey="Goulet M" first="M." last="Goulet">M. Goulet</name></noRegion><name sortKey="Bedard, P J" sort="Bedard, P J" uniqKey="Bedard P" first="P. J." last="Bedard">P. J. Bedard</name><name sortKey="Di Paolo, T" sort="Di Paolo, T" uniqKey="Di Paolo T" first="T." last="Di Paolo">T. Di Paolo</name><name sortKey="Falardeau, P" sort="Falardeau, P" uniqKey="Falardeau P" first="P." last="Falardeau">P. Falardeau</name><name sortKey="Grondin, R" sort="Grondin, R" uniqKey="Grondin R" first="R." last="Grondin">R. Grondin</name><name sortKey="Maltais, S" sort="Maltais, S" uniqKey="Maltais S" first="S." last="Maltais">S. Maltais</name><name sortKey="Morissette, M" sort="Morissette, M" uniqKey="Morissette M" first="M." last="Morissette">M. Morissette</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003562 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003562 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:00-0338490
|texte= Regulation by chronic treatment with cabergoline of dopamine D1 and D2 receptor levels and their expression in the striatum of Parkinsonian-Monkeys
}}
| This area was generated with Dilib version V0.6.29. |  |